Project Grant R01AI181923
- This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental immunological research at the University of Toledo Health Science Campus Division. The award of $162,000 obligated on September 1, 2025, with completion targeted for August 31, 2027, funds research to elucidate the cardioprotective role of fetal-derived CD8+ T cells during viral-induced myocarditis....
- Summary of Federal Project Grant Award The National Institute of Allergy and Infectious Diseases (NIAID) awarded $159,300 to La Jolla Institute for Immunology on April 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support investigator-initiated research on human upper airway immune memory kinetics and durability against respiratory pathogens. The research project, which extends through March 31, 2031, focuses on characterizing upper airway immune cell...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $453,750 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2026. The award funds investigator-initiated biomedical research examining the role of zinc finger (ZNF) proteins in the establishment and maintenance of Human...
- Federal Grant Award Summary Tufts University School of Medicine received a $7.04 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the mechanisms of nuclear egress in herpesviruses. The award, effective August 1, 2025, through July 31, 2029, supports research that expands understanding of how herpesviruses manipulate host cell membranes to export viral capsids from...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Connecticut Health Center a $263,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 20, 2026, with a completion date of March 31, 2028. The award supports investigator-initiated biomedical research focused on identifying and developing antiviral therapeutics targeting Herpes Simplex Virus (HSV) alkaline nuclease as a novel drug...
- Federal Grant Award Summary Emory University received a $234,156 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on capsid assembly mechanisms of Kaposi Sarcoma Associated Herpesvirus (KSHV). The award, issued February 28, 2026, with completion scheduled for October 31, 2028, supports fundamental research aimed at understanding how herpesvirus capsids assemble—a...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports investigator-initiated research examining the role of the immunometabolite L-2-hydroxyglutarate (L-2HG) in natural killer (NK) cell antiviral immunity. Awarded to Weill Medical College of Cornell University on December 23, 2025, with a total obligation of $109,076.00 and a completion date of June 30, 2029, this...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a Project Grant of $243,600 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 23, 2026, with completion targeted for January 31, 2028. This award supports investigator-initiated biomedical research examining the role of CLCC1, an endoplasmic reticulum protein, in facilitating herpesvirus nuclear egress—the process...
- Federal Project Grant Award Summary Emory University received a $346,214 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 27, 2025, with a completion date of January 31, 2028. The research project, titled "Drivers of the Beneficial Effects of Influenza A Virus Co-infection," focuses on understanding the fundamental viral processes underlying how multiple...
- This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...
INTERSECTION OF SEVERE RESPIRATORY INFECTION AND VIRAL LATENCY - PROJECT SUMMARY/ABSTRACT THE ROLE THAT CHRONIC VIRAL INFECTION PLAYS IN SHAPING THE IMMUNE SYSTEM AND RESPONSES TO SUBSEQUENT INFECTIONS IS CRITICALLY IMPORTANT BUT UNDERSTUDIED. IT IS ESTIMATED THAT >80% OF ADULTS HARBOR AT LEAST 5 LATENT HERPESVIRUSES. GAMMAHERPESVIRUSES ESTABLISH LATENCY IN IMMUNE CELLS, FURTHER HIGHLIGHTING THE IMPORTANCE OF UNDERSTANDING HOW LATENCY IMPACTS HOST IMMUNE RESPONSES TO SUBSEQUENT INFECTIONS. CURRENTLY THERE IS A SUBSTANTIAL KNOWLEDGE GAP IN THE ROLE PLAYED BY LATENCY AND/OR MECHANISMS BY WHICH PRIOR GAMMAHERPESVIRUS INFECTION CONTRIBUTES TO SUBSEQUENT IMMUNE RESPONSES, PARTICULARLY IN THE LUNG. DESPITE THE KNOWN DELETERIOUS EFFECTS OF HERPESVIRUS INFECTION ON HUMAN HEALTH, EMERGING EVIDENCE SUGGESTS THE POSSIBILITY THE LATENT HERPESVIRUS INFECTION MAY ACTUALLY PROTECT FROM SECONDARY INFECTIONS. THEREFORE, TO UNCOVER KEY MECHANISMS BY WHICH LATENCY IMPACTS SUBSEQUENT IMMUNE RESPONSES, I PROPOSE THE FOLLOWING: I WILL TEST THE PREMISE THAT GAMMAHERPESVIRUS LATENCY IMPACTS HOST PROTECTION DURING SUBSEQUENT PULMONARY INFECTIONS THAT ARE PREVALENT ACROSS KINGDOMS AND DISSECT HOW LATENTLY INFECTED IMMUNE CELLS INTRINSICALLY RESPOND TO HETEROLOGOUS PATHOGENS. I WILL ALSO DELINEATE THE IMPACT OF THE MICROBIOTA ON ESTABLISHMENT AND MAINTENANCE OF HERPESVIRUS LATENCY GIVEN THE CRITICAL IMPACT OF THE MICROBIOTA ON IMMUNE RESPONSES AND THE BROAD USE OF POTENT ANTIBIOTICS IN MEDICAL PRACTICE. THESE DISTINCT BUT EQUALLY IMPORTANT DIRECTIVES WILL FILL KEY KNOWLEDGE GAPS. AT THE COMPLETION, I EXPECT TO DEFINE THE ROLE OF LATENCY AND REACTIVATION ON HUMAN IMMUNE RESPONSIVENESS AND DEVELOP A FRAMEWORK TO DEFINE HOW THE BALANCE BETWEEN MICROBIOTA AND SECONDARY INFECTIONS ARE INFORMED BY LATENCY. MOREOVER, THIS STUDY IS CLINICALLY RELEVANT AND FUNDAMENTALLY SIGNIFICANT AS THESE FINDINGS HAVE THE POTENTIAL TO DEFINE NOVEL MECHANISMS AND PATHWAYS IMPORTANT FOR PATHOGEN CONTROL AND TISSUE REPAIR. IN ALIGNMENT WITH THE STEPHEN I. KATZ FUNDING MECHANISM, THIS PROPOSAL REPRESENTS A NEW DIRECTION FOR MY RESEARCH PROGRAM. WHILE I HAVE PREVIOUSLY STUDIED CYTOKINE REGULATION OF HERPESVIRUS LATENCY DURING MY DOCTORAL THESIS AND IDENTIFIED PROTECTIVE MICROBIAL METABOLITES IN PULMONARY INFECTION AS A POSTDOCTORAL FELLOW, I HAVE NOT INVESTIGATED HOW VIRAL LATENCY INTRINSICALLY IMPACTS IMMUNE CELL FUNCTION DURING SECONDARY PULMONARY INFECTIONS OR HOW THE MICROBIOTA INFLUENCES THE ESTABLISHMENT AND MAINTENANCE OF LATENCY. THIS NEW INVESTIGATION WILL REQUIRE ACQUISITION OF NOVEL TOOLS AND TECHNOLOGIES THAT WILL RESHAPE MY RESEARCH PROGRAM AND ENHANCE ITS SCOPE AND IMPACT. I AM PERFECTLY POSITIONED TO DIRECT AND EXECUTE THIS UNIQUE LINE OF INVESTIGATION AS I HAVE EXPERTISE ACROSS MULTIPLE RELEVANT DOMAINS INCLUDING VIROLOGY, MICROBIOLOGY, IMMUNOLOGY, AND CRITICAL CARE MEDICINE. ADDITIONALLY AS AN EARLY STAGE INVESTIGATOR, I HAVE ESTABLISHED COLLABORATIONS WITH EXPERTS ACROSS DIVERSE DOMAINS OF MICROBIAL PATHOGENESIS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $629.5k | 5/7/26 | ||
| Not listed | $645.1k | 4/21/25 | ||
| Not listed | $645.1k | 4/21/25 | ||
| Not listed | $63.6k | 9/4/24 | ||
| Not listed | $63.6k | 9/4/24 |